Jazz Pharmaceuticals plc [NASDAQ: JAZZ] plunged by -$0.68 during the normal trading session on while it closed the day at $108.64.
Jazz Pharmaceuticals plc stock has also loss -5.38% of its value over the past 7 days. However, JAZZ stock has inclined by 3.98% in the 3 months of the year. Over the past six months meanwhile, it has lost -8.26% and lost -11.67% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for JAZZ stock reached $6.71 billion, with 62.26 million shares outstanding and 59.64 million shares in the current float. Compared to the average trading volume of 663.35K shares, JAZZ reached a trading volume of 4223036 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Jazz Pharmaceuticals plc [JAZZ]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JAZZ shares is $178.18 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JAZZ stock is a recommendation set at 1.42. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Jazz Pharmaceuticals plc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 05, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on January 03, 2024, representing the official price target for Jazz Pharmaceuticals plc stock. Previously, the target price had yet another drop from $170 to $135, while UBS kept a Neutral rating on JAZZ stock.
The Average True Range (ATR) for Jazz Pharmaceuticals plc is set at 2.88, with the Price to Sales ratio for JAZZ stock in the period of the last 12 months amounting to 1.72. The Price to Book ratio for the last quarter was 1.78, with the Price to Cash per share for the same quarter was set at 32.08. Price to Free Cash Flow for JAZZ in the course of the last twelve months was 6.42 with Quick ratio for the last quarter at 1.90.
JAZZ stock trade performance evaluation
Jazz Pharmaceuticals plc [JAZZ] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.38. With this latest performance, JAZZ shares dropped by -2.65% in over the last four-week period, additionally sinking by -8.26% over the last 6 months – not to mention a drop of -24.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JAZZ stock in for the last two-week period is set at 41.20, with the RSI for the last a single of trading hit 33.95, and the three-weeks RSI is set at 44.95 for Jazz Pharmaceuticals plc [JAZZ]. The present Moving Average for the last 50 days of trading for this stock 109.63, while it was recorded at 113.18 for the last single week of trading, and 115.36 for the last 200 days.
Jazz Pharmaceuticals plc [JAZZ]: An insightful look at the core fundamentals
Jazz Pharmaceuticals plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.25.
Earnings per share (EPS) analysis for Jazz Pharmaceuticals plc [JAZZ] stock
With the latest financial reports released by the company, Jazz Pharmaceuticals plc posted 4.84/share EPS, while the average EPS was predicted by analysts to be reported at 4.93/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.09. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JAZZ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Jazz Pharmaceuticals plc go to 4.85%.
Jazz Pharmaceuticals plc [JAZZ]: Institutional Ownership
There are presently around $96.25%, or 99.11%% of JAZZ stock, in the hands of institutional investors. The top three institutional holders of JAZZ stocks are: VANGUARD GROUP INC with ownership of 6.32 million shares, which is approximately 10.1103%. BLACKROCK INC., holding 6.15 million shares of the stock with an approximate value of $$655.94 million in JAZZ stocks shares; and BLACKROCK INC., currently with $$264.75 million in JAZZ stock with ownership which is approximately 3.9666%.
